Amyloid inhibitory peptides

A method for treating Alzheimer's disease or type 2 diabetes, wherein said method comprises administering, to a patient in need of such treatment, a peptide having an amino acid sequence according to formula o

• wherein
• Z1 and Z2 are selected from the following pairs
• a) cysteine and cysteine,
• b) aspartic acid and lysine, or lysine and aspartic acid,
• c) aspartic acid and ornithine, or ornithine and aspartic acid,
• d) aspartic acid and 2,4-diaminobutyric acid, or 2,4-diaminobutyric acid and aspartic acid,
• e) aspartic acid and 2,3-diaminopropionic acid, or 2,3-diaminopropionic acid and aspartic acid,
• f) glutamic acid and lysine, or lysine and glutamic acid,
• g) glutamic acid and ornithine, or ornithine and glutamic acid,
• h) glutamic acid and 2,4-diaminobutyric acid, or 2,4-diaminobutyric acid and glutamic acid,
• i) glutamic acid and 2,3-diaminopropionic acid, or 2,3-diaminopropionic acid and glutamic acid;
• with denoting a covalent bond between Z1 and Z2, thus providing for a cyclization of the peptide;
• X1, X2, X3, X4, X5, X6, and X7 are, independently at each occurrence, selected from glycine, asparagine, valine, histidine, leucine, serine, alanine, and threonine;
• F is, independently at each occurrence, phenylalanine;
• L is leucine;
• U is, independently at each occurrence, selected from arginine, homoarginine, citrulline, ornithine, lysine, and norleucine;
• G is glycine;
• I is isoleucine;
• wherein Z1, Z2, X1-X7, F, L, U, G and I are L-amino acid residues or D-amino acid residues, or some of Z1, Z2, X1-X7, F, L, U, G and I are L-amino acid residues and others are D-amino acid residues;
• and pharmaceutically acceptable salts, esters, solvates, polymorphs and modified forms thereof.